Evidence map›Paper›PMID 33464098›Full record

ReviewThe journal of physical chemistry. B2021

Defining the Neuropathological Aggresome across

Gregory-Neal Gomes, Zachary A Levine

Open access · greenAbstract readReview
In one paragraph

Review in The journal of physical chemistry. B, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Gregory-Neal GomesDepartment of Pathology, Yale School of Medicine, New Haven, Connecticut 06520, United States.
Zachary A LevineDepartment of Pathology, Yale School of Medicine, New Haven, Connecticut 06520, United States.ORCID 0000-0003-0182-1081
Yale University · US

Funding

Yale Study Support Suite (YES3): Dashboard and Web Portal Software Supporting Research Workflow through integrated, customizable REDCap External ModulesP30AG021342 · NIA · YALE UNIVERSITY · PI Albert C Shaw · 2002 to 2026
$37.9M
AMYLOIDOGENIC INDUCTION OF CELLULAR SENESCENCE IN ALZHEIMER'S DISEASER01AG068285 · NIA · YALE UNIVERSITY · PI MIRANKER, ANDREW D. · 2020 to 2024
$2.1M
REPURPOSING PRION PROTEINS AS TRANSLATIONAL AMYLOID-TARGETING THERAPEUTICS FOR ALZHEIMER'S DISEASEK01AG062752 · NIA · YALE UNIVERSITY · PI LEVINE, ZACHARY ALAN · 2020 to 2021
$254k
NIA NIH HHS K01 AG062752NIA NIH HHS P30 AG021342NIA NIH HHS R01 AG068285
6 · The paper itself

Abstract

The loss of proteostasis over the life course is associated with a wide range of debilitating degenerative diseases and is a central hallmark of human aging. When left unchecked, proteins that are intrinsically disordered can pathologically aggregate into highly ordered fibrils, plaques, and tangles (termed amyloids), which are associated with countless disorders such as Alzheimer's disease, Parkinson's disease, type II diabetes, cancer, and even certain viral infections. However, despite significant advances in protein folding and solution biophysics techniques, determining the molecular cause of these conditions in humans has remained elusive. This has been due, in part, to recent discoveries showing that soluble protein oligomers, not insoluble fibrils or plaques, drive the majority of pathological processes. This has subsequently led researchers to focus instead on heterogeneous and often promiscuous protein oligomers. Unfortunately, significant gaps remain in how to prepare, model, experimentally corroborate, and extract amyloid oligomers relevant to human disease in a systematic manner. This Review will report on each of these techniques and their successes and shortcomings in an attempt to standardize comparisons between protein oligomers across disciplines, especially in the context of neurodegeneration. By standardizing multiple techniques and identifying their common overlap, a clearer picture of the soluble neuropathological aggresome can be constructed and used as a baseline for studying human disease and aging.

Indexed as

Alzheimer DiseaseDiabetes Mellitus, Type 2AmyloidAmyloid beta-PeptidesComputer SimulationHumansAmyloidAmyloid beta-Peptides

Identifiers

PMID33464098
PMCPMC8362740
OpenAlexW3121475547

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.